United States Migraine Drugs Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32
                     United States Migraine 
Drugs Market Research 
and Forecast Report 
2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
IMARC Group is  a g lobal  management  consul t ing f i rm that  he lps the wor ld ’s  most  ambi t ious 
changemakers  to create a las t ing impact .  Across the s ix  major  cont inents  and 100+ count r ies ,  we 
work a longside our  bus iness par tners  as one team wi th  a common ambi t ion to achieve unparal le led 
resul ts ,  gain a compet i t ive edge,  and t ransform indust r ies .  IMARC Group excels  in  unders tanding 
i ts  c l ients ’  bus iness pr ior i t ies  and del iver ing ta i lored solut ions that  dr ive meaningfu l  outcomes.  Our 
c l ient  base spans over  3,000 organizat ions in  the pr ivate,  publ ic ,  and soc ia l  sectors ,  ranging f rom 
high-growth s tar tups to For tune 500 companies.
We prov ide a comprehensive sui te of  market  entry  and expansion serv ices.  Our of fer ings inc lude 
thorough market  assessment ,  feas ib i l i ty  s tudies,  company incorporat ion ass is tance,  fac tory  setup 
suppor t ,  regulatory  approvals and l icens ing navigat ion,  branding,  market ing and sales st rategies,  
compet i t ive landscape and benchmark ing analyses,  pr ic ing and cost  research,  and procurement  
research.  These serv ices are des igned to ass is t  companies in  evaluat ing market  oppor tuni t ies ,  
set t ing up new ent i t ies ,  navigat ing regulatory landscapes,  boost ing brand v is ib i l i ty ,  analyz ing 
compet i tors,  and opt imiz ing procurement  s t rategies.
A cc o r d i ng  t o  t h e  l a t e s t  r e p o r t  b y  I MA R C  G r ou p ,  t i t l e d  " U n i t e d  S t a t e s  M i g r a i n e  D r u g s  
Ma r k e t :  I n d u s t r y  T r e n d s ,  S h a r e ,  S i z e ,  Gr o w th ,  O p p o r t u n i ty  a n d  F o r e ca s t  2 0 2 4 -
20 3 2 , "  t h e  U n i t e d  S ta t e s  m i g r a i n e  d r u g s  ma r k e t  s i z e  i s  p ro j e c t e d  t o  e xh i b i t  a  g r o w t h  
r a t e  ( C A G R )  o f  1 5 .9 5 %  d u r i n g  2 0 2 4 - 20 3 2 .
P ha r m ac e u t i c a l  c o mp a n i es  a r e  i n v es t i n g  h e a v i l y  i n  r es e a r ch  an d  d e v e l o pm e n t  t o  
Report i n t r o d u ce  n o ve l  t he r a p i e s ,  i n c l ud i n g  b i o l o g i c s  a n d  p e r s o n a l i ze d  me d i c i n e  op t i o n s ,  
ca t e r i n g  t o  p a t i e n t s  w i t h  v a ry i n g  n e e d s .  T h e  m a rk e t  i s  a l so  s e e i n g  a  s h i f t  t o w a r d s  n o n -
i n va s i v e  t r e a t m e n t  o p t i o n s ,  r e f l e c t i n g  t he  g r o w i ng  d e m an d  f o r  c o nv e n i e n ce  a n d  p a t i e n t  
Highlight and co m f o r t .  A d d i t i on a l l y ,  r e g u l a to r y  ap p r o v a l s  f o r  i n n o v a t i v e  d ru g s ,  su c h  as  C GR P  
i n h i b i t o r s ,  a r e  ex p a n d i n g  t r ea t m e n t  o p t i o n s ,  f u r t h e r  f u e l i n g  m a rk e t  ex pa n s i on .  
Description T he  ma r k e t  i s  b e co m i ng  i n c r e a s i n g l y  c o m pe t i t i v e ,  w i t h  e s ta b l i s h e d  ph a r ma c e u t i ca l  co m p a n i es  an d  ne w  en t r a n t s  s t r i v i n g  t o  c a p t u r e  a  s h a r e  t h r o u gh  s t r a t eg i c  p a r t ne r s h i p s ,  
me r g e rs ,  a nd  a c qu i s i t i o n s .  A s  h e a l th c a r e  p r o v i d e r s  p r i o r i t i z e  e f f e c t i v e  m i g r a i n e  
ma n a g em e n t ,  t h e  de m a n d  f o r  a dv a n c e d  t h e r a p i e s  i s  e xp e c t ed  t o  c o n t i n u e  i t s  u p w a rd  
t ra j e c t o r y .
R eq u e s t  f o r  a  P D F  sa m p l e  o f  t h i s  re p o r t :  
h t t p s : / /w w w . i ma r c g r o u p . co m / u n i te d - s t a t e s -m i g r a i n e - d r u gs - m ar k e t / re q u e s t sa m p l e
Report Description
Uni ted  S ta tes  Migra i ne  Drugs  Market  T rends:
The  Un i t ed  S ta tes  m igra ine  d rugs  marke t  i s  expand ing  due  t o  seve ra l  key  d r i ve rs  and emerg ing  t rends .  The  
inc reas ing  preva lence  o f  m ig ra ine  among  the  popu la t ion ,  i n f luenced by  s t ress ,  l i f es t y l e  changes ,  and  r i s ing  
awareness  o f  m ig ra ine  as  a  s ign i f i can t  hea l th  i ssue ,  i s  d r i v i ng  demand fo r  e f fec t i ve  t r ea tmen ts .  Pharmaceu t i ca l  
compan ies  a re  inves t ing  heav i l y  in  r esearch  and deve lopmen t ,  l ead ing  t o  the  i n t roduc t ion  o f  nove l  d rugs ,  i nc lud ing  
b io log i cs  and CG RP (ca lc i t on in  gene- re la t ed  pep t ide )  inh ib i t o r s ,  wh ich  a re  ga in ing  rap id  marke t  accep tance .  
The  grow ing  focus  on  pe rsona l i zed  med ic ine  i s  a lso  in f luenc ing  marke t  dynamics ,  w i th  t rea t men ts  be ing  t a i lo red  to  
ind iv idua l  pa t ien t  p ro f i l es  f o r  improved  ou tcomes .  Add i t i ona l l y ,  t he  marke t  i s  w i tness ing  a  sh i f t  t owards  p reven t i ve  
t rea tment s ,  as  pa t i en ts  and  hea l t hca re  p rov ide rs  seek  to  r educe  t he  f requency  and sever i t y  o f  m ig ra ine  a t tacks  ra ther  
t han  mere ly  add ress ing  symptom s.  The  inc reas ing  adopt i on  o f  d ig i t a l  t he rapeu t i cs  and  te lemed ic ine  fo r  m igra ine  
management  f u r t he r  suppor t s  marke t  g rowt h ,  o f f e r ing  pa t i en ts  more  access ib le  and conven ien t  t r ea tmen t  op t ions .
Vi ew Report  TOC,  F igures and  Tab les :  h t tps: / / www. i marcgroup .com/un i ted -states -mi gra ine -d rugs-market
Treatment Type Insights:
• Abortive Treatment
• Preventive Treatment
 
Drug Type Insights:
• Triptans
• Ergot Alkaloids
Report 
• NSAIDs
Segmentation • Acetylchol ine Inhibitors/ Neurotoxins
• Ditans
• CGRP mAbs
• Others
Route of Administration Insights:
• Oral
• Injectable
• Others
Distribution Channel Insights:
• Hospital -Based Pharmacies
• Retai l  Pharmacies
Report • Others
Segmentation
Regional Insights:
• Northeast 
• Midwest 
• South 
• West
How has the United States migraine drugs market performed 
so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the United States 
migraine drugs market?
Key 
Questions What is the breakup of the United States migraine drugs market on the basis of treatment type?
Answered in 
What is the breakup of the United States migraine drugs 
the Report market on the basis of drug type?
What is the breakup of the United States migraine drugs 
market on the basis of route of administration?
What is the breakup of the United States migraine drugs 
market on the basis of distribution channel?
What are the various stages in the value chain of the United 
States migraine drugs market? 
What are the key driving factors and challenges in the 
United States migraine drugs?
Key What is the structure of the United States migraine drugs 
market and who are the key players?
Questions 
Answered in What is the degree of competition in the United States migraine drugs market?
the Report
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4    U n i t e d  S t a t e s  M i g r a i n e  D r u g s  M a r k e t  -  I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     M a r k e t  D y n a m i c s
    4 . 3     I n d u s t r y  T r e n d s
    4 . 4     C o m p e t i t i v e  I n t e l l i g e n c e
5    U n i t e d  S t a t e s  M i g r a i n e  D r u g s  M a r k e t  L a n d s c a p e
    5 . 1     H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
    5 . 2     M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
6    U n i t e d  S t a t e s  M i g r a i n e  D r u g s  M a r k e t  -  B r e a k u p  b y  T r e a t m e n t  T y p e
    6 . 1     A b o r t i v e  T r e a t m e n t
        6 . 1 . 1  O v e r v i e w
        6 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 1 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    6 . 2     P r e v e n t i v e  T r e a t m e n t  
        6 . 2 . 1  O v e r v i e w
        6 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 2 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
       
7    U n i t e d  S t a t e s  M i g r a i n e  D r u g s  M a r k e t  -  B r e a k u p  b y  D r u g  T y p e
    7 . 1     T r i p t a n s
        7 . 1 . 1  O v e r v i e w
        7 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 1 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    7 . 2     E r g o t  A l k a l o i d s
        7 . 2 . 1  O v e r v i e w
        7 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 2 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    7 . 3     N S A I D s
        7 . 3 . 1  O v e r v i e w
Table of         7 . 3 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 3 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    7 . 4     A c e t y l c h o l i n e  I n h i b i t o r s /  N e u r o t o x i n s
Contents         7 . 4 . 1  O v e r v i e w        7 . 4 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 4 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    7 . 5     D i t a n s
        7 . 5 . 1  O v e r v i e w
        7 . 5 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 5 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    7 . 6     C G R P  m A b s
        7 . 6 . 1  O v e r v i e w
        7 . 6 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 6 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    7 . 7     O t h e r s
        7 . 7 . 1  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 7 . 2  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )     
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /u n i t ed - s ta t es -m i g ra i ne -d ru gs -m
a rke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: